BioXcel Shares Jump 19% in After-Hours Trading: Key Information to Consider
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Updated: Aug 27 20250mins
Stock Performance: BioXcel Therapeutics Inc. (BTAI) saw a 19.09% increase in after-hours trading, reaching $6.24, following anticipation for key clinical trial results.
Investor Call Announcement: The company is hosting an investor call to discuss topline results from its SERENITY At-Home Phase 3 safety trial of BXCL501, aimed at treating agitation in bipolar disorder and schizophrenia patients at home.
Trial Details: The SERENITY trial involved 200 patients over 12 weeks, focusing on the safety of BXCL501 compared to a placebo, with potential implications for expanding treatment options beyond medical supervision.
Regulatory Support: BXCL501 has received Breakthrough Therapy and Fast Track designations from the FDA, which could expedite approval processes if trial outcomes are favorable, while the company utilizes AI for identifying new therapeutic uses.
BTAI.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BTAI
Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 10.67 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 2.070
Low
4.00
Averages
10.67
High
18.00
Current: 2.070
Low
4.00
Averages
10.67
High
18.00
Mizuho
Neutral
maintain
$2 -> $4
2025-09-12
Reason
Mizuho
Price Target
$2 -> $4
2025-09-12
maintain
Neutral
Reason
Mizuho raised the firm's price target on BioXcel Therapeutics to $4 from $2 and keeps a Neutral rating on the shares. The firm cites the positive Phase 3 SERENITY At-Home study data for BXCL501 for the target doubling. Mizuho's risk-adjusted sales estimate for Igalmi in peak year 2037 is now projected at $390M across three indications, from $325M prior. However, the firm sees continued uncertainty around what type of financing BioXcel will undertake to provide more financial stability.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$8 -> $10
2025-08-15
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$8 -> $10
2025-08-15
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $10 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm cites "heightened enthusiasm" for BXCL501's prospects for the target increase. The analyst views the SERENITY readout as low-risk and believes BioXcel could file for the expanded label of BXCL501 by the end of this year and may receive the label extension in the back half of 2026.
Lucid Capital
Lucid Capital
Buy
maintain
$15
2025-07-15
Reason
Lucid Capital
Lucid Capital
Price Target
$15
2025-07-15
maintain
Buy
Reason
Lucid Capital reiterates a Buy rating on BioXcel Therapeutics with a $15 price target after the company announced that the U.S. Patent and Trademark Office approved its patent application which covers the use of a single dose of dexmedetomidine in an oromucosal formulation for treating acute agitation in schizophrenia or bipolar patients with QT prolongation under six microseconds. Once officially granted, the patent will be eligible for inclusion in the FDA's Orange Book as the 14th listed patent for Igalmi and is expected to expire on January 12, 2043, pending any patent term adjustments, the analyst tells investors in a research note.
Lucid Capital
NULL
to
Buy
initiated
$66
2025-06-25
Reason
Lucid Capital
Price Target
$66
2025-06-25
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of BioXcel Therapeutics with a Buy rating and $66 price target. BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer's disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer's disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.
See All Ratings
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key objectives of BioXcel's virtual roundtable on December 8?
How does BioXcel's AI technology contribute to drug re-innovation in neuroscience?
How might self-administered treatments impact the future of mental health care?
What changes could the roundtable catalyze in the acute care industry?